Number of the records: 1  

Synergism of BCL-2 family inhibitors facilitates selective elimination of senescent cells

  1. 1.
    0566015 - ÚMG 2023 RIV US eng J - Journal Article
    Ryšánek, David - Vašicová, Pavla - Kolla, Jayaprakash Narayana - Sedlák, David - Anděra, Ladislav - Bártek, Jiří - Hodný, Zdeněk
    Synergism of BCL-2 family inhibitors facilitates selective elimination of senescent cells.
    Aging. Roč. 14, č. 16 (2022), s. 6381-6414. ISSN 1945-4589
    R&D Projects: GA MŠMT(CZ) LM2018129; GA MŠMT(CZ) EF18_046/0016045; GA ČR(CZ) GA18-14259S; GA MŠMT(CZ) LM2018130; GA MŠMT LX22NPO5102
    Institutional support: RVO:68378050
    Keywords : homoharringtonine * cellular senescence * bcl-2 * mcl-1 * senolytics
    OECD category: Cell biology
    Impact factor: 5.2, year: 2022
    Method of publishing: Open access
    https://www.aging-us.com/article/204207/text

    Accumulation of senescent cells in tissues with advancing age participates in the pathogenesis of several human age-associated diseases. Specific senescent secretome, the resistance of senescent cells to apoptotic stimuli, and lack of immune system response contribute to the accumulation of senescent cells and their adverse effects in tissues. Inhibition of antiapoptotic machinery, augmented in senescent cells, by BCL-2 protein family inhibitors represents a promising approach to eliminate senescent cells from tissues. This study aimed to explore synergistic and selective senolytic effects of anti-apoptotic BCL-2 family targeting compounds, particularly BH3 mimetics.
    Permanent Link: https://hdl.handle.net/11104/0337451

     
    FileDownloadSizeCommentaryVersionAccess
    aging-v14i16-204207.pdf18.5 MBPublisher’s postprintopen-access
     
Number of the records: 1  

  This site uses cookies to make them easier to browse. Learn more about how we use cookies.